Breaking News Instant updates and real-time market news.

PTLA

Portola Pharmaceuticals

$27.16

-0.39 (-1.42%)

20:15
09/24/18
09/24
20:15
09/24/18
20:15

Portola granted orphan status for cerdulatinib

The FDA granted Portola Pharmaceuticals orphan status for cerdulatinib, its treatment of peripheral T-cell lymphoma. Reference Link

  • 31

    Dec

PTLA Portola Pharmaceuticals
$27.16

-0.39 (-1.42%)

09/12/18
WBLR
09/12/18
NO CHANGE
WBLR
Outperform
Portola manufacturing review timeline encouraging, says William Blair
Portola Pharmaceuticals last night announced that the FDA assigned a PDUFA date of December 31, 2018, for the recently submitted prior approval supplement for the generation 2 manufacturing process of Andexxa, equating to a four-month review period, William Blair analyst Matt Phipps tells investors in a research note. Portola management had conservatively guided to a six-month review, the analyst notes. He's encouraged by this review timeline, pointing out that approval in 2018 would provide Portola with full commercial supply for Q1 of 2019. Phipps remains confident in the potential of Andexxa to achieve blockbuster sales and believes Andexxa alone is worth "significantly more than the company at current price levels." He keeps an Outperform rating on Portola Pharmaceuticals.
09/07/18
SBSH
09/07/18
NO CHANGE
Target $50
SBSH
Buy
Departure of Portola's CCO is a 'clear positive,' says Citi
Citi analyst Yigal Nochomovitz said the resignation of Portola Pharmaceuticals' CCO is a "clear positive" and is not much of a surprise given his lack of experience in commercial operations. The analyst believes Portola can now substantially re-shape top-level management with a new COO with the right operational experience ahead of both the Andexxa and Bevyxxa launches. Norchomovitz rates Portola Pharmaceuticals a Buy with a $50 price target.
08/27/18
08/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. First Majestic (AG) upgraded to Outperform from Market Perform at BMO Capital with analyst Ryan Thompson citing his expectations of gross margin improvement following the shutdown of the high-cost La Guitarra mine and the integration of the high-margin San Dimas mine. 2. Papa John's (PZZA) upgraded to Buy from Neutral at Kalinowski with analyst Mark Kalinowski saying he believes the reported hiring of Bank of America and Lazard increases the odds of a favorable outcome over the next 12 months, including the possibility of an acquisition. 3. Portola Pharmaceuticals (PTLA) upgraded to Neutral from Underperform at Credit Suisse with analyst Vamil Divan citing Johnson & Johnson (JNJ) and Bayer's (BAYRY) presentation of disappointing data for Xarelto in the acute medically ill population at ESC. 4. Bancolombia (CIB) upgraded to Neutral from Sell at Citi. 5. AK Steel (AKS) and Steel Dynamics (STLD) were upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/27/18
MSCO
08/27/18
NO CHANGE
MSCO
Equal Weight
Portola may be up 'somewhat' on Xarelto trial failure, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted the failure of Johnson & Johnson's (JNJ)MARINER study, which was examining Xarelto, a competing anticogulant to Portola's (PTLA) BevyxXa. MARINER's failure to demonstrate a statistically significant result of reducing symptomatic VTE or death due to VTE is expected by Harrison to send Portola shares up "somewhat," but he believes most investors had already lowered their expectations for the BevyxXa franchise after the Q2 report, making the impact modest. He maintains an Equal Weight rating on Portola shares, which are up 3% to $29 per share in early trading.

TODAY'S FREE FLY STORIES

LODE

Comstock Mining

$0.22

-0.0124 (-5.42%)

06:52
10/16/18
10/16
06:52
10/16/18
06:52
Hot Stocks
Comstock Mining completes sampling program in Daytn adit »

Comstock Mining announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMC

Omnicom

$69.48

0.8 (1.16%)

06:51
10/16/18
10/16
06:51
10/16/18
06:51
Earnings
Omnicom reports Q3 EPS $1.32, consensus $1.21 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

YMAB

Y-mAbs Therapeutics

$21.46

0.06 (0.28%)

06:51
10/16/18
10/16
06:51
10/16/18
06:51
Initiation
Y-mAbs Therapeutics initiated  »

Y-mAbs Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$427.40

-0.18 (-0.04%)

06:50
10/16/18
10/16
06:50
10/16/18
06:50
Hot Stocks
BlackRock CEO: Not worried about inflation at the moment »

Says we aren't going…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

JNJ

Johnson & Johnson

$133.75

-0.03 (-0.02%)

06:49
10/16/18
10/16
06:49
10/16/18
06:49
Earnings
Johnson & Johnson reports Q3 adj. EPS $2.05, consensus $2.03 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

  • 28

    Oct

JNJ

Johnson & Johnson

$133.75

-0.03 (-0.02%)

, GMXAY

Genmab

$0.00

(0.00%)

06:49
10/16/18
10/16
06:49
10/16/18
06:49
Hot Stocks
Genmab reports Darzalex sales of $498M in Q3 »

Genmab (GMXAY) announced…

JNJ

Johnson & Johnson

$133.75

-0.03 (-0.02%)

GMXAY

Genmab

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

  • 28

    Oct

CMA

Comerica

$83.69

-1.04 (-1.23%)

06:45
10/16/18
10/16
06:45
10/16/18
06:45
Earnings
Comerica reports Q3 adj. EPS $1.86, consensus $1.76 »

Reports Q3 Tier 1 capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 24

    Oct

INFY

Infosys

$9.90

0.16 (1.64%)

06:45
10/16/18
10/16
06:45
10/16/18
06:45
Earnings
Infosys reports Q3 EPS 13c, consensus 13c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 21

    Oct

  • 22

    Oct

BLK

BlackRock

$427.40

-0.18 (-0.04%)

06:40
10/16/18
10/16
06:40
10/16/18
06:40
Hot Stocks
BlackRock CEO: Rising wages impacting corporate profits »

Says stocks in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

TSLA

Tesla

$259.58

0.47 (0.18%)

06:40
10/16/18
10/16
06:40
10/16/18
06:40
Hot Stocks
Musk: Tesla owners who ordered full self-driving version to get chip upgrade »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 13

    Nov

  • 13

    Dec

QCOM

Qualcomm

$64.18

-0.1 (-0.16%)

06:38
10/16/18
10/16
06:38
10/16/18
06:38
Periodicals
Qualcomm, FTC ask judge to delay ruling to pursue settlement, Reuters reports »

Qualcomm and the U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

TPR

Tapestry

$43.09

-0.72 (-1.64%)

06:38
10/16/18
10/16
06:38
10/16/18
06:38
Upgrade
Tapestry rating change  »

Tapestry upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

WMT

Walmart

$93.85

-0.93 (-0.98%)

06:36
10/16/18
10/16
06:36
10/16/18
06:36
Earnings
Walmart cuts FY19 adjusted EPS view to $4.65-$4.80 from $4.90-$5.05 »

Consensus is $4.79. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 28

    Oct

  • 15

    Nov

GSV

Gold Standard Ventures

$1.70

-0.09 (-5.03%)

06:36
10/16/18
10/16
06:36
10/16/18
06:36
Hot Stocks
Gold Standard Ventures reports from two holes at Dark Star deposit »

Gold Standard Ventures…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$93.85

-0.93 (-0.98%)

06:35
10/16/18
10/16
06:35
10/16/18
06:35
Earnings
Breaking Earnings news story on Walmart »

Walmart cuts FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 28

    Oct

  • 15

    Nov

HBB

Hamilton Beach

$19.40

0.5 (2.65%)

06:33
10/16/18
10/16
06:33
10/16/18
06:33
Hot Stocks
Hamilton Beach appoints Michelle Mosier as CFO »

Hamilton Beach announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWR

Genesee & Wyoming

$84.16

0.83 (1.00%)

06:33
10/16/18
10/16
06:33
10/16/18
06:33
Hot Stocks
Genesee & Wyoming reports September traffic of 257,723 carloads, down 0.7% y/y »

Genesee & Wyoming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

FHN

First Horizon

$15.99

-0.11 (-0.68%)

06:32
10/16/18
10/16
06:32
10/16/18
06:32
Earnings
First Horizon reports Q3 EPS 36c, consensus 36c »

Reports Q3 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 05

    Nov

AZN

AstraZeneca

$37.46

0.31 (0.83%)

, MRK

Merck

$69.46

-0.31 (-0.44%)

06:31
10/16/18
10/16
06:31
10/16/18
06:31
Hot Stocks
AstraZeneca, Merck: FDA grants LYNPARZA Orphan Drug Designation »

AstraZeneca (AZN) and…

AZN

AstraZeneca

$37.46

0.31 (0.83%)

MRK

Merck

$69.46

-0.31 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 19

    Oct

  • 19

    Oct

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

  • 11

    Jan

  • 16

    Feb

AMZN

Amazon.com

$1,760.99

-27.64 (-1.55%)

06:29
10/16/18
10/16
06:29
10/16/18
06:29
Periodicals
Amazon may launch robots with new-generation tech in 2019, DigiTimes reports »

Amazon is likely to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 25

    Oct

ESPR

Esperion

$44.94

-1.21 (-2.62%)

, MRK

Merck

$69.46

-0.31 (-0.44%)

06:29
10/16/18
10/16
06:29
10/16/18
06:29
Initiation
Esperion, Merck initiated  »

Esperion initiated with a…

ESPR

Esperion

$44.94

-1.21 (-2.62%)

MRK

Merck

$69.46

-0.31 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 19

    Oct

  • 19

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

AMZN

Amazon.com

$1,760.99

-27.64 (-1.55%)

06:22
10/16/18
10/16
06:22
10/16/18
06:22
Periodicals
Amazon CEO calls current internet a 'confirmation bias machine', BI reports »

Amazon CEO Jeff Bezos…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 25

    Oct

TSQ

Townsquare Media

$7.40

0.09 (1.23%)

06:21
10/16/18
10/16
06:21
10/16/18
06:21
Conference/Events
Townsquare Media management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

TLRY

Tilray

$165.71

17.56 (11.85%)

06:21
10/16/18
10/16
06:21
10/16/18
06:21
Initiation
Tilray initiated  »

Tilray initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPRO

Spero Therapeutics

$9.83

0.23 (2.40%)

06:18
10/16/18
10/16
06:18
10/16/18
06:18
Downgrade
Spero Therapeutics rating change  »

Spero Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.